A phase III EGF104900 trial enrolled 296 heavily pretreated HER + MBC patients and showed that HL had a statistically significant advantage over lapatinib monotherapy in PFS (3 months vs 2 months, P = .008) but not in OS (12.9 months vs 9.7 months, P = .11).7 This study had a relatively low PFS mainly because patients had a median of four lines of previous treatment and no chemotherapy was added in the anti‐HER2 therapy. Here, ERBB2 is linked to Hodgkins lymphoma.